NCT02425241 - Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

September 30, 2016

Conditions

HIV

Interventions

BIOLOGICAL

pSG2.HIVconsv DNA vaccine

pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.

BIOLOGICAL

ChAdV63.HIVconsv booster vaccine

ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.

BIOLOGICAL

MVA.HIVconsv booster vaccine

MVA.HIVconsv 2 x 10\^8 pfu at week 20

DRUG

CPHPC

40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.

OTHER

Placebo

Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.

Trial Locations (1)

National Amyloidosis Centre, London